Clinical Trial: Rituxan® (rituximab, molecule that regulates immune response) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: Rituxan® (rituximab, molecule that regulates immune response)

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 20
Medication: Rituxan®
Location: CA
Contact Information
Elena Kornyeyeva
(415) 514-2467

Funding:

Genentech

Description

Open-label study of safety and tolerability of rituximab in people with neuromyelitis optica (NMO, a disease similar to MS) or at high risk for developing NMO (this includes people with optic neuritis or transverse myelitis, and may include people with MS as well as these symptoms)

Share